Acadian Asset Management LLC Satsuma Pharmaceuticals, Inc. Transaction History

Acadian Asset Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.61 - $5.06 $167,792 - $1.39 Million	275,069 New	275,069 $246,000
Q4 2021 Feb 10, 2022	SELL	$4.15 - $6.24 $21,799 - $32,778	-5,253 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$4.54 - $7.17 $2,347 - $3,706	517 Added 10.92%	5,253 $24,000
Q2 2021 Aug 11, 2021	BUY	$4.8 - $7.25 $22,732 - $34,336	4,736 New	4,736 $33,000
Q1 2021 May 11, 2021	SELL	$4.57 - $7.18 $135,354 - $212,657	-29,618 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$3.56 - $5.09 $70,502 - $100,802	19,804 Added 201.79%	29,618 $137,000
Q3 2020 Nov 09, 2020	BUY	$3.85 - $28.47 $37,783 - $279,404	9,814 New	9,814 $38,000

Ticker STSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,587,500
Description
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Acadian Asset Management LLC with notifications on news.